首页> 外国专利> PHARMACEUTICAL COMPOSITION FOR INDUCING EXERCISE MIMETIC EFFECT

PHARMACEUTICAL COMPOSITION FOR INDUCING EXERCISE MIMETIC EFFECT

机译:诱发运动性仿效的药物组合物

摘要

The present disclosure relates to a pharmaceutical composition for inducing an exercise mimetic effect, which contains an α1-adrenergic receptor agonist as an active ingredient, and a method for screening a drug for inducing an exercise mimetic effect using the α1-adrenergic receptor agonist.;The α1-adrenergic receptor agonist of the present disclosure increases the expression of p-AMPK, PPARδ and PGC-1α, which play key roles in maintaining and regulating energy metabolic activity in vivo, thereby increasing glucose uptake into skeletal muscle cells, suppressing adipocyte differentiation and lipid accumulation, reducing abdominal fat and body weight as well as regulating mitochondrial metabolic disorders and suppressing inflammatory responses. Accordingly, the α1-adrenergic receptor agonist can be usefully used to prevent and treat diseases requiring AMPK activation (metabolic diseases, cardiovascular diseases, inflammatory disease, etc.).
机译:本发明涉及一种以α 1 -肾上腺素能受体激动剂为有效成分的诱导模拟运动效果的药物组合物,以及使用该药物组合物筛选诱导模拟运动效果的药物的方法。 α 1 -肾上腺素能受体激动剂;本发明的α 1 -肾上腺素能受体激动剂增加p-AMPK,PPARδ和PGC-1α的表达。在维持和调节体内能量代谢活动,从而增加对骨骼肌细胞的葡萄糖摄取,抑制脂肪细胞分化和脂质蓄积,减少腹部脂肪和体重以及调节线粒体代谢紊乱和抑制炎症反应中起关键作用。因此,α 1 -肾上腺素能受体激动剂可有效地用于预防和治疗需要AMPK激活的疾病(代谢性疾病,心血管疾病,炎性疾病等)。

著录项

  • 公开/公告号US2020046658A1

    专利类型

  • 公开/公告日2020-02-13

    原文格式PDF

  • 申请/专利权人 CELLVERTICS CO. LTD.;

    申请/专利号US201916591713

  • 申请日2019-10-03

  • 分类号A61K31/165;A61P3/10;G01N33/573;A61P3/04;G01N33/94;

  • 国家 US

  • 入库时间 2022-08-21 11:24:57

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号